The clinical syndrome of 5-fluorouracil cardiotoxicity.
5-fluorouracil (FUra) is one of the most frequently used drugs in cancer treatment, particularly in combination with other agents. Its activity when administered as an infusion rather than a bolus has led to a renewed and increased use. A cardiotoxicity that mimics ischemia has been associated with the administration of FUra in cancer patients. This cardiotoxicity may manifest itself as: (a) dysrythmias with and without cardiorespiratory symptoms (b) ECG changes with and without cardiorespiratory symptoms (c) cardiorespiratory symptoms with and without ECG changes (d) acute myocardial infarct; symptoms and ECG changes (e) ventricular dysfunction (f) cardiogenic shock and (g) sudden death. Several case studies which illustrate the cardiotoxic sequelae that may be associated with the use of this drug are discussed. The incidence, contributing factors, risk factors and mechanisms underlying this phenomenon are undetermined. No appropriate recommendations for monitoring patients or for predicting those patients that will develop such toxicity while receiving FUra can be made at present. Prospective studies to determine the true incidence, spectrum and mechanisms causing this syndrome are ongoing and required for its understanding and prevention.
Ensley
J F
JF
Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan.
Patel
B
B
Kloner
R
R
Kish
J A
JA
Wynne
J
J
al-Sarraf
M
M
D000328:Adult; D000368:Aged; D003327:Coronary Disease / Q000139:chemically induced / Q000188:drug therapy; D003645:Death, Sudden / Q000209:etiology; D004562:Electrocardiography; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects*; D006331:Heart Diseases / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced / Q000188:drug therapy; D012008:Recurrence
D005472:Fluorouracil